Bd reports fourth quarter and full year fiscal 2023 financial results

Execution of bd 2025 strategy driving durable, broad-based growth q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis q4 revenue from base business (which excludes covid-only diagnostic testing) grew 7.3% as reported, 6.3% currency-neutral or 7.0% organic q4 gaap and adjusted diluted eps from continuing operations of $0.53 and $3.42, respectively fy23 revenue of $19.4 billion increased 2.7% as reported and 4.5% on a currency-neutral basis fy23 revenue from base business grew 5.1% as reported, 7.0% currency-neutral or 5.8% organic fy23 gaap and adjusted diluted eps from continuing operations of $5.10 and $12.21, respectively company issues fy24 guidance including 5.75% organic revenue growth at midpoint of 5.25% to 6.25% range; announces 52nd consecutive year of dividend increases franklin lakes, n.j. , nov. 9, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2023, which ended september 30, 2023.
BDX Ratings Summary
BDX Quant Ranking